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Germacrene B and seline-1,3,7-trien-
8-one oxide are the major com-
pounds in essential oil (EO).
Eugenia uniﬂora leaf EO presented
antidepressant-like activity.
The EO reduced the linoleic acid oxi-
dation.
TheEOreduced the lipidperoxidation
on cortex, hippocampus and cerebel-
lum.
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In thisworkwe evaluated antidepressant-like effect of E. uniﬂora leaves EO employing the tail suspension




oral route (p.o.) in mice and the doses of 10 and 50mg/kg exhibited antidepressant-like action in the
TST. The effect of EO (10mg/kg) was prevented by the pretreatment of mice with ketanserin (5mg/kg,
intraperitoneal), prazosin (0.1mg/kg, i.p.) and yohimbine (0.1mg/kg, i.p.). In addition, further analysis of
the in vitro antioxidant effect of the EO was made against lipid oxidation. The results revealed that EO
has a potent antioxidant activity and therapeutic potential for the development of phytomedicines with
antidepressant and antioxidant properties.ugenia uniﬂora
. Introduction
Depression is characterized by awide range of debilitating emo-
ional and physical symptoms such as changed mood and lack of
nterest in the surroundings [2]. Numerous neural pathways are
nvolved in the pathophysiology of depression, and a great num-
er of neurotransmitters participate in the primary mechanisms of
rugs action [5]. Depression has been estimated to affect up to 21%
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of theworld’s population and according toWHO’s prediction, itwill
be the second most common disease in 2020 [31].
Some authors have suggested the involvement of oxidative
stress in neurological and psychiatric disorders [15]. The oxidative
stress occurswhen redoxhomeostasis is challengedby free radicals
and reactive oxygen species (ROS), due to either overproductions
or deﬁciencies in antioxidants defenses. The brain is particularly
vulnerable to oxidative damage, since it has comparatively high
oxygen consumption, modest antioxidant defenses, and a lipid-
rich constitution, with the presence of redox-catalytic metals such
iron and cupper, and neurotransmitters with reducing potential
[18]. The vulnerability of the brain and the association between
neurodegenerative changes and psychiatric disorders suggest
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athogenesis of depression, and that antioxidant supplementation
ay be a target in this treatment [6].
In the search for new molecules useful for the treatment of neu-
ological disorders, medicinal plants have emerged as a source for
he development of drugs, demonstrating pharmacological poten-
ial and playing an important role for patients who respond poorly
o conventional treatments [9].
In fact, many studies have addressed the potential of plant-
erived essential oils (EOs) on the central nervous system, as
atural antidepressants, to relieve anxiety, and stress [4,17,25]. EOs
re natural products generally obtained from medicinal plants that
xhibit a variety of pharmacological properties [3].
The leaves of Eugenia uniﬂora, popularly known as “pitanga”, are
sed in Brazilian folk medicine in the treatment of rheumatism,
tomach diseases, disorders of the digestive tract, hypertension,
nd also to diminish blood pressure [1,30]. Recently, Colla et al. [12]
tudied the antidepressant-like effect of a hydro-alcoholic extract
f E. uniﬂora leaves in the tail suspension test (TST). However, the
xtract did not present antidepressant-like effect in the TST even
t concentration of 100mg/kg.
Additionally, we have recently reported the antioxidant,
ntibacterial and antifungal activities of the pitanga leaf EO and no
cute toxicity was observed, with a LD50 higher than 200mg/kg
28]. Based on these promising results and aiming to extend
ur studies about E. uniﬂora leaves EO, we decide to evalu-
te its antidepressant-like effect and the possible involvement
f serotoninergic and adrenergic systems; moreover, the in vitro
ntioxidant effect of the E. uniﬂora leaves EO was studied against
ipid oxidation.
. Materials and methods
Male Swiss mice of 2–3 months old (25–30g) were maintaining
t 22–25 ◦C, under 12h:12h light/dark cycles, with free access to
ood and water and at a relative humidity of 60±20%. This study
as approved by the Federal University of Pelotas Committee of
nimal Experimentation (CEEA 2622) and the experimental proto-
ol was in compliance with National Institutes of Health Guide for
are and Use of Laboratory Animals. All efforts were made to min-
mize animal suffering and to reduce the number of animals used
n the experiments. All experiments were performed with separate
roups of animals (n=5–6), totalizing 60 animals, approximately,
nd each animal was used only once.
The E. uniﬂora leaves EO was obtained by steam distillation and
ts chemical composition was analyzed by gas chromatography
oupled with mass spectrometer (GC/MS).
For the in vitro assays, EO was dissolved in dimethyl sulfoxide
DMSO) and the control was DMSO alone; for the in vivo assays, EO
as diluted in canola oil and administered in a constant volume
f 10ml/kg body weight and canola oil alone was the control. The
rugs (positive control and antagonists) were dissolved in saline
nd control animals received appropriate vehicle (saline solution
r canola oil).
For the evaluation of the antidepressant-like effect, the ani-
als were pre-treated with different doses of EO (1–50mg/kg, per
ral, (p.o.) or ﬂuoxetine (32mg/kg, p.o.) or canola oil (10ml/kg)
0min before of the tail suspension test (TST). In the TST, animals
re placed in an inescapable situation and the antidepressant-like
ctivity is expressed by the decrease of immobility time, an effect
hat is exhibited by conventional antidepressants [13]. This is a
ell characterized behavioral model predictive of antidepressant
ctivity.
The total immobility time induced by tail suspension was mea-
ured according to the method described by Steru [26]. The mice
ere suspended on the edge of a table 50 cm above the ﬂoor byetters 544 (2013) 105–109
adhesive tape placed approximately 1 cm from the tip of the tail.
Immobility time, deﬁned as the absence of escape-oriented behav-
ior, was scored over 6min as previously described [26].
In order to investigate the possible involvement of serotonin-
ergic system on the antidepressant-like effect of the EO on the
TST in mice, distinct groups of animals were pretreated with dif-
ferent antagonists. Animals were pretreated with WAY-100635,
a selective antagonist of 5-HT1A receptors (0.1mg/kg, subcuta-
neous, s.c.), ketanserin, a non-selective antagonist of 5-HT2A/2C
receptors (5mg/kg, intraperitoneal, i.p) or ondansetron, a selec-
tive antagonist of 5-HT3 receptors (1mg/kg, i.p.), 15min before
the administration of the EO (10mg/kg, p.o.) or vehicle (canola
oil).
To address the possible involvement of the adrenergic system
in the antidepressant-like effect of EO, animals were pretreated
with prazosin (1mg/kg, i.p.), a selective antagonist of ˛1 adren-
ergic receptor, yohimbine (1mg/kg, i.p.), a selective antagonist
of ˛2 adrenergic receptor or vehicle and after 15min they
received EO (10mg/Kg, p.o.) or vehicle and were tested in the TST
1h later.
The locomotor and exploratory behavior was assessed in the
open ﬁeld test (OFT). Each animal was placed individually at the
center of the apparatus and observed for 5min to record the loco-
motor (number of segments crossed with the four paws) and
exploratory activities (expressed by the number of time rearing
on the hind limbs) [29]. The animals were pretreated with E. uni-
ﬂora EO (1–50mg/Kg, p.o.) and, after 1h, they were observed in the
OFT.
Considering the role of oxidative stress on pathophysiology of
depression and to extend our studies about the in vitro antioxidant
effect of the E. uniﬂora leaves EO, we evaluated the effect of the EO
on linoleic acid peroxidation assay and SNP-induced lipid peroxi-
dation onhippocampus, cortex and cerebellumofmice. These brain
structures were used since they are implicated in the pathogenesis
of depression (cortex and hippocampus) [24] while cerebellum has
been indicated as an area under negative functional connectivity
from the hippocampus seen in depressive subjects [8].
Linoleic acid was used as a lipid matrix to evaluate the effect
of EO on Fe2+-ascorbic acid- induced lipid peroxidation. The ability
of EO (10–500g/ml) to inhibit the linoleic acid peroxidation was
determined at 532nm by the method of Choi [11].
To evaluate the effect of E. uniﬂora EO in the lipid peroxidation
on the hippocampus, cortex and cerebellum, the levels of malondi-
aldehyde (MDA), an end product of lipid peroxidation, were used
as a biomarker. For this purpose, mice were euthanized by cervical
dislocation and cerebral tissue was rapidly removed, and the hip-
pocampus, cortex and cerebellum were separated. After that, the
tissueswere immediatelyhomogenized, centrifuged, thepelletwas
discarded, and a low-speed supernatant (S1)was used to determine
the effects of different concentrations of EO on SNP- induced lipid
peroxidation.
SNP was used as a classical inductor of lipid peroxidation [23]
and the levels of MDA were determined spectrophotometrically by
the thiobarbituric acid reactive substances assay (TBARS), accord-
ing to the protocol of Ohkawa [21].
The results are presented as means± standard error mean
(SEM). Statistical analysis was performed using a one-way or two-
way analysis of variance (ANOVA) followed by the appropriate
multiple comparison tests. The in vitro assays was performed in
duplicate and repeated at least three times; for the in vivo assays,
six animals were used per group. Differences were considered sta-
tistically signiﬁcant at a p value of 0.05. The IC50 (concentration
of sample required to inhibit 50% of lipid peroxidation) and ID50
(dose necessary to reduce in 50% the immobility time when com-
pared to the control group) values were calculated from the graph
of % inhibition vs. concentration.
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Fig. 1. Effect of acute administration of E. uniﬂora EO on immobility time in the
TST. F is the positive control ﬂuoxetine (32mg/kg, p.o.). Values are presented as





















Effect of E. uniﬂora leaves essential oil on linoleic acid peroxidation.








a Control (DMSO alone). Values are presented as mean± SEM. Asterisks represent





wompared to the control group by one-way ANOVA followed by the Newman-Keuls
ultiple range test.
. Results
The chemical composition of the EO was analyzed by GC/MS.
he chromatogram of the EO permitted the identiﬁcation of
even compounds that comprised approximately 90% of all con-
tituents. The EO contains mainly no-oxygenated sesquiterpenes,
ollowed by oxygenated ones. The major compounds in the EO
re germacrene B (22%), selina-1,3,7-trien-8-one-oxide (19%), -
aryophyllene (13%), germacrene A (11.6%), germacrene D (11.4%),
elina-1,3,7-trien-8-one (9.5%) and curzerene (4%).
The EO reduced signiﬁcantly the immobility time at doses
qual and higher than 10mg/kg (58.9% decrease), while ﬂuoxe-
ine reduced by 56.3% (Fig. 1) when compared to the control group
canola oil). The ID50 was 9.1±1.2mg/ml and the maximum inhi-
ition (Imax) for the EO on the TST was 72.8±17.1%.
Pretreatment of mice with ketanserin prevents the anti-
mmobility action of the EO. A two-way ANOVA revealed a sig-
iﬁcant interaction between the pretreatment and the treatment
F(1,10) =8.66, p=0.0147), as can be seen on Fig. 2. On the other
and, the pretreatment of mice with WAY100635 ((F(1,14) =2.53,






























































ig. 2. Effect of pretreatment of mice with (A) WAY100635, (B) ketanserin and (C) ond
resented as mean± standard error mean (SEM) (n=6). One asterisk represents p<0.05
ith EO group by two-way ANOVA followed by Newman-Keuls multiple range test.The data were analyzed by one-way ANOVA followed by the Newman–Keuls mul-
tiple comparison test.
the antidepressant-like effect of E. uniﬂora leaves EO (Fig. 2A and
C).
The pretreatment with adrenergic antagonists revealed that
both blocked the antidepressant-like effect of EO, increasing
the immobility time when compared to the E. uniﬂora EO
group (Fig. 3). Two-way ANOVA revealed a signiﬁcant interaction
between the pretreatment with prazosin and the treatment with
EO (F(1,15) =7.11,p=0.0176) andbetweenyohimbineandEO treat-
ments (F(1,13) =12.84, p=0.003).
Considering that the antidepressant-like activity of the E. uni-
ﬂora leaves EO on the TST may be subjected to the presence of
components that induce hyperactivity or cause a locomotor prob-
lem, given a false positive or negative effect respectively,micewere
submitted to the OFT. The administration of EO did not alter signif-
icantly the locomotor and exploratory parameters when compared
to the control group (data not shown).
The effect of E. uniﬂora EO on the linoleic oxidation is depicted
on Table 1. The EO inhibited the oxidation of linoleic acid in con-
centrations equal and higher than 50g/ml with an IC50 value of
325.0±66.1g/ml and an Imax of 60.5±6.1%, while DMSO alone
had not effect.
The SNP induced lipid peroxidation in hippocampus, cortex and
cerebellum while the E. uniﬂora EO reduced SNP-induced lipid
peroxidation at concentrations equal or greater than 50g/ml in
















ansetron on the antidepressant-like effect of the E. uniﬂora leaves EO. Values are
when compared to the vehicle group and (#) represents p<0.01 when compared




















































































trror mean (SEM) (n=6). Three asterisks represents p<0.001 when compared to th
NOVA followed by the Newman-Keuls multiple range test.
3.30±5.10g/ml, Imax 53.0±1.90%) and cerebellum of mice
47.0±2.80g/ml, Imax 53.0±14.6%, Table 2).
For the ﬁrst time the antidepressant-like effect of E. uniﬂora EO
n the TST was reported. This effect is mediated by the modula-
ionof serotoninergic and adrenergic systems. Interestingly, in vitro
ssays revealed that the EO inhibits the lipid oxidation in the assays
f linoleic acid oxidation and SNP-induced lipid peroxidation in
erebral structures.
. Discussion
In the present work, we demonstrate that E. uniﬂora EO pro-
uced antidepressant-like effect in the TST at doses of 10 and
0mg/kg. Considering the negative results of Colla et al. [12]
egarding the antidepressant-like effect of hydro-alcoholic extract
f E. uniﬂora L leaves in the TST, the hydro alcoholic extract
id not present antidepressant-like effect in the TST, probably,
he amount of volatile compounds present in the EO, like oxy-
enated and non-oxygenated sesquiterpenes are responsible for its
ntidepressant-like effect.
Many studies have suggested that the activation of 5-HT2 recep-
ors can be related in the regulation of mood disorders [10].
hese receptors are widely distributed throughout brain struc-
ures that are important on the pathophysiology of depression, like
re-frontal cortexandhippocampus [19]. Conventional antidepres-
ants are based on the enhancement of monoamines in the brain,
ike serotonin, norepinephrine and dopamine that are involved in
he pathophysiology of depression [14].According with our results, the antidepressant-like effect of E.
niﬂora leaves EO involves the modulation of receptors 5-HT2A/2C,
ince the pretreatment of mice with ketanserin, an antagonist of
able 2
ffect of E. uniﬂora L leaves EO on SNP-induced lipid peroxidation.
SNP-induced lipid peroxidation (nmol MDA/g tissue)
Hippocampus Cortex Cerebellum
Control 769.2±23.83* 628.90 ± 150.40* 632.90 ± 45.24*
Induced 1400±163.2# 1458.00 ± 167.20# 1220.0 ± 77.91#
EO 1g/ml 1744.0±268.1 1793.0 ± 236.50 1437.0 ± 280.50
EO 10g/ml 888.90±14.14 568.80 ± 195.00** 758.10 ± 109.50**
EO 50g/ml 775.10±176.80* 797.30 ± 163.90* 586.10 ± 40.87**
EO 100g/ml 647.80±228.40* 791.90 ± 86.10* 515.70 ± 125.00**
IC50 (g/ml) – 93.30 ± 5.10 47.0 ± 2.80
Imax (%) 37.5±12.5 53.0 ± 1.90 53.0 ± 14.60




# Represent signiﬁcant difference from the control (tissue alone, p<0.05).
he data were analyzed by one-way ANOVA followed by the Newman–Keuls mul-
iple range test.icle group and (#) represents p<0.05 when compared with EO group by two-way
these receptors, signiﬁcantly prevent the anti-immobility effect of
the EO.
Besides the serotoninergic, the adrenergic system is clas-
sically implicated in the pathophysiology of depression [16],
and compounds that affect the adrenergic neurotransmission,
such as noradrenaline reuptake inhibitors or monoamine oxidase
inhibitors, are currently used to treat depression [22].
In this study, the pretreatment ofmicewith prazosin, a selective
antagonist of ˛1 adrenoreceptor, has blocked the antidepressant-
like effect of E. uniﬂora EO. Furthermore, the pretreatment of
animalswithyohimbine, a˛2 adrenoreceptor antagonist, improved
the immobility time. This ﬁnding indicates that ˛2 is also involved
in the action of EO.
Thus, the antidepressant-like effect of the E. uniﬂora EO appears
to be involved, at least in part, with serotoninergic and adrenergic
systems.
Recent clinical evidences have showed the co-existence
between increased oxidative stress and depression symptoms in
patients [20]. Since the E. uniﬂora EO presented antidepressant-
like effect, we extend our studies to evaluate its in vitro antioxidant
effect.
E. uniﬂora EO decreased the levels of linoleic acid oxidation in
concentrations ranging from 50 to 500g/ml and presents effect
against the SNP-induced lipid oxidation on the studied cerebral
regions. Reactive oxygen derived species (ROS) partially reduced
are produced as part of normal physiological and metabolic pro-
cesses in aerobic organisms. Excessive production of ROS can lead
to oxidative stress, an imbalance between the pro-oxidant and
antioxidant species [18]. Oxidative stress is known to affect lipid
membrane through lipid peroxidation and also to oxidize proteins
and DNA.
Alterations in phospholipids may induce changes in membrane
viscosity and in various neurotransmitter systems like serotonin
(5-HT) and noradrenaline [27]. However, it is not clear if oxidative
stress is a cause or a result of depression [7].
5. Conclusion
The present work demonstrated that the antioxidant activ-
ity and the antidepressant-like effect of E. uniﬂora leaves EO
are mediated by the modulation of serotoninergic and adrener-
gic systems. Together, these results suggest that the E. uniﬂora
EO may have therapeutic value. However, more studies are nec-
essary to elucidate others possible mechanisms involved on the
antidepressant-like effect of the EO as well as to evaluate its effect
in a long term exposition.Acknowledgements
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